Clinical Trials
Aurora Biosynthetics Launches to Transform RNA Therapeutics Manufacturing in Asia-Pacific
Aurora Biosynthetics, a pioneering advanced RNA therapeutics manufacturing company, announced its official launch. This heralds a new era in RNA therapeuti...
September 13, 2024 | News
HighTide Therapeutics Presents Promising Data on HTD1801 for Type 2 Diabetes at EASD 2024
HighTide Therapeutics, Inc. (2511.HK), a clinical-stage biopharmaceutical company dedicated to developing multifunctional therapies for chronic liver and m...
September 12, 2024 | News
Avistone Biotechnology Presents Promising Clinical Results of Dual c-MET and EGFR Inhibitors for NSCLC at WCLC 2024
Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision...
September 11, 2024 | News
Ractigen Therapeutics Reports Positive Clinical Data from ALS-SOD1 Trial of RAG-17
Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, announced promising clinical data from an Inve...
September 11, 2024 | News
Nuance Pharma Completes Patient Recruitment for Pivotal ENHANCE-CHINA COPD Study
Nuance Pharma announced it has completed the recruitment of patients for the ENHANCE-CHINA (NCT05743075) study, after planned number of patients have ...
September 11, 2024 | News
GenAssist Doses First DMD Patient with Pioneering Base Editing Drug GEN6050X in Clinical Trial
GenAssist Ltd (GenAssist), announced the first DMD patient dosed with its base editing drug, GEN6050X injection, in an investigator-initiated trial (IIT). ...
September 10, 2024 | News
Daiichi Sankyo and AstraZeneca’s Datopotamab Deruxtecan Shows Superior Progression-Free Survival in Biomarker-Positive NSCLC Patients
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan demonstrated meaningfully greater magnitude of progression-free survival benefit in p...
September 09, 2024 | News
Merck Launches Global Phase III Trial of Oral Cladribine for Generalized Myasthenia Gravis Treatment
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG) Cl...
September 06, 2024 | News
Antabio Completes Phase 1 Trial of MEM-ANT3310, Advancing Novel Antibacterial Treatment for Drug-Resistant Infections
Antabio, a private biopharmaceutical company developing novel and highly differentiated antibacterial treatments for critical priority pathogens, with a pa...
September 06, 2024 | News
Arsenal Biosciences Closes $325 Million Series C Funding to Advance Next-Gen CAR T-Cell Therapies for Solid Tumors
Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid t...
September 05, 2024 | News
GC Biopharma and Hanmi Pharmaceutical Receive FDA Clearance for Phase 1/2 Trial of First Once-Monthly Subcutaneous Treatment for Fabry Disease
Co-development of innovative new drug for the treatment of Fabry disease as "the world's first once-monthly subcutaneous treatment" Improves efficacy co...
September 04, 2024 | News
Innovent Biologics Receives FDA Fast Track Designation for PD-1/IL-2α Bispecific Antibody in Advanced Melanoma Treatment
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
September 04, 2024 | News
Simcere Zaiming and TargetRx Forge Strategic Partnership for Groundbreaking ALK/ROS1 Dual Inhibitor in China
Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx In...
September 03, 2024 | News
Nxera Pharma and Neurocrine Biosciences Report Positive Phase 2 Results for NBI-1117568 in Schizophrenia Treatment
Nxera Pharma – formerly known as Sosei Group or Sosei Heptares – notes the announcement by its partner Neurocrine Biosciences Inc. (&ldqu...
August 30, 2024 | News
Most Read
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
